Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Mar;8(3):215-224.
doi: 10.1002/sctm.18-0053. Epub 2018 Dec 28.

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial

Jose Matas  1 , Mario Orrego  1 , Diego Amenabar  1 , Catalina Infante  2 , Rafael Tapia-Limonchi  2   3 , Maria Ignacia Cadiz  2 , Francisca Alcayaga-Miranda  2   3   4 , Paz L González  4 , Emilio Muse  5 , Maroun Khoury  2   3   4 , Fernando E Figueroa  3   4   6 , Francisco Espinoza  2   3   6
Affiliations
Clinical Trial

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial

Jose Matas et al. Stem Cells Transl Med. 2019 Mar.

Abstract

Knee osteoarthritis (OA) is a leading cause of pain and disability. Although conventional treatments show modest benefits, pilot and phase I/II trials with bone marrow (BM) and adipose-derived (AD) mesenchymal stromal cells (MSCs) point to the feasibility, safety, and occurrence of clinical and structural improvement in focal or diffuse disease. This study aimed to assess the safety and efficacy of the intra-articular injection of single or repeated umbilical cord-derived (UC) MSCs in knee OA. UC-MSCs were cultured in an International Organization for Standardization 9001:2015 certified Good Manufacturing Practice-type Laboratory. Patients with symptomatic knee OA were randomized to receive hyaluronic acid at baseline and 6 months (HA, n = 8), single-dose (20 × 106 ) UC-MSC at baseline (MSC-1, n = 9), or repeated UC-MSC doses at baseline and 6 months (20 × 106 × 2; MSC-2, n = 9). Clinical scores and magnetic resonance images (MRIs) were assessed throughout the 12 months follow-up. No severe adverse events were reported. Only MSC-treated patients experienced significant pain and function improvements from baseline (p = .001). At 12 months, Western Ontario and Mc Master Universities Arthritis Index (WOMAC-A; pain subscale) reached significantly lower levels of pain in the MSC-2-treated group (1.1 ± 1.3) as compared with the HA group (4.3 ± 3.5; p = .04). Pain Visual Analog scale was significantly lower in the MSC-2 group versus the HA group (2.4 ± 2.1 vs. 22.1 ± 9.8, p = .03) at 12 months. For total WOMAC, MSC-2 had lower scores than HA at 12 months (4.2 ± 3.9 vs. 15.2 ± 11, p = .05). No differences in MRI scores were detected. In a phase I/II trial (NCT02580695), repeated UC-MSC treatment is safe and superior to active comparator in knee OA at 1-year follow-up. Stem Cells Translational Medicine 2019;8:215&224.

Keywords: Disability; Knee; Mesenchymal stromal cells; Osteoarthritis; Pain.

PubMed Disclaimer

Conflict of interest statement

C.I., R.T.‐L., M.I.C., F.A.‐M., P.L.G., and M.K. have declared employment/leadership position with Cells for Cells. F.E. has declared employment/leadership position and intellectual property or patent holder with Cells for Cells. The other authors indicated no potential conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart. Abbreviation: MSC, mesenchymal stromal cell.
Figure 2
Figure 2
Selection of UC‐mesenchymal stromal cell (MSC) batch. (A): TSP2 secretion analysis from three UC‐MSCs batches of different donors. All data presented as mean ± SEM, n = 4, * p < .05. (B): Differentiation potential of different UC‐MSC batch tested. Scale bars 200 mm, n = 3. (C): UC‐MSC proliferation rate through the assessment of doubling times, p < .05, n = 3. Abbreviations: TSP2, thrombospondin‐2; UC, umbilical cord.
Figure 3
Figure 3
Efficacy outcomes. (A–C): Comparison with baseline in each group. (A): WOMAC‐A pain subscale. (B): WOMAC‐C function subscale. (C): Total WOMAC. (D): OMERACT‐OARSI Responder Index Criteria. Abbreviation: HA, hyaluronic acid; MSC, mesenchymal stromal cell; WOMAC, Western Ontario and Mc Master Universities Arthritis Index.
See this image and copyright information in PMC

Comment in

References

    1. Abbott JH, Usiskin IM, Wilson R et al. The quality‐of‐life burden of knee osteoarthritis in New Zealand adults: A model‐based evaluation. PLoS One 2017;12:e0185676. - PMC - PubMed
    1. Losina E, Walensky RP, Reichmann WM et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011;154:217–226. - PMC - PubMed
    1. Liu Q, Niu J, Huang J et al. Knee osteoarthritis and all‐cause mortality: The Wuchuan Osteoarthritis Study. Osteoarthr Cartil 2015;23:1154–1157. - PubMed
    1. Gore M, Tai KS, Sadosky A et al. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: A retrospective claims database analysis. J Med Econ 2011;14:497–507. - PubMed
    1. McKenna MT, Michaud CM, Murray CJ et al. Assessing the burden of disease in the United States using disability‐adjusted life years. Am J Prev Med 2005;28:415–423. - PubMed

Publication types

Substances